脑动静脉畸形的血管内治疗:一项实用性随机试验登记研究中患者的临床结局
TOBAS研究包含两个随机试验和多个登记研究,报告了治愈性栓塞和前栓塞登记研究的结果。治愈性栓塞登记中14%患者死亡或依赖(mRS>2),前栓塞登记中12%;栓塞单独闭塞AVM的比例分别为30%和12%,严重不良事件常见。作者认为血管内治疗作用仍不确定,应尽可能在随机试验背景下进行。
要点
- 治愈性栓塞登记中14%患者死亡或残疾(mRS>2),前栓塞登记中为12%。
- 栓塞单独确认闭塞AVM在治愈性尝试中为30%,前栓塞中为12%。
- 严重不良事件在治愈性栓塞中为26%,前栓塞中为23%,包括新发症状性出血。
核心结论
- 栓塞作为脑AVM的治愈性治疗往往不完全,出血并发症频繁,即使指定意图为术前或SRS前的前栓塞。
- 由于血管内治疗的作用仍不确定,作者认为在可能时应优先在随机试验的背景下提供。
研究设计与样本
- TOBAS是一项全纳入性实用性研究,包含两个随机试验和多个登记研究;本报告报告了治愈性栓塞和前栓塞登记研究的结果。
- 2014年6月至2021年5月,TOBAS共招募1010例患者;116例选择栓塞作为主要治愈性治疗,92例选择手术或SRS前的前栓塞。
- 治愈性栓塞登记中106/116例(91%)有临床和血管造影结局;前栓塞登记中77/92例(84%)有临床和血管造影结局。
主要发现
- 治愈性栓塞登记中70%的AVM破裂,62%为低级别AVM(Spetzler-Martin I或II级);前栓塞登记中70%破裂,58%为低级别。
- 主要结局死亡或残疾(mRS>2)在治愈性栓塞登记106例中发生15例(14%,95%CI 8%-22%),其中未破裂AVM 4/32例(12%,95%CI 5%-28%),破裂AVM 11/74例(15%,95%CI 8%-25%);前栓塞登记77例中发生9例(12%,95%CI 6%-21%),其中未破裂AVM 4/23例(17%,95%CI 7%-37%),破裂AVM 5/54例(9%,95%CI 4%-20%),随访2年。
- 栓塞单独确认闭塞AVM在治愈性尝试106例中为32例(30%,95%CI 21%-40%),在前栓塞登记77例中为9例(12%,95%CI 6%-21%)。
- 治愈性栓塞尝试的106例中28例发生严重不良事件(26%,95%CI 18%-35%),包括21例新发症状性出血(20%,95%CI 13%-29%);其中5例出血在既往未破裂AVM中(n=32;16%,95%CI 5%-33%)。
- 前栓塞登记77例中18例发生严重不良事件(23%,95%CI 15%-34%),包括12例新发症状性出血(16%,95%CI 9%-26%);其中3例出血在既往未破裂AVM中(3/23;13%,95%CI 3%-34%)。
关键数值与推荐
- 主要结局为末次随访时死亡或依赖(mRS>2);次要结局包括血管造影结果、围手术期严重不良事件和导致mRS>2的永久性治疗相关并发症。
临床怎么用
- 作者认为血管内治疗的作用仍不确定,应尽可能在随机试验的背景下提供。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of endovascular treatment in the management of patients with brain arteriovenous malformations (AVMs) remains uncertain. AVM embolization can be offered as stand-alone curative therapy or prior to surgery or stereotactic radiosurgery (SRS) (pre-embolization). The Treatment of Brain AVMs Study (TOBAS) is an all-inclusive pragmatic study that comprises two randomized trials and multiple registries. METHODS: Results from the TOBAS curative and pre-embolization registries are reported. The primary outcome for this report is death or dependency (modified Rankin Scale [mRS] score > 2) at last follow-up. Secondary outcomes include angiographic results, perioperative serious adverse events (SAEs), and permanent treatment-related complications leading to an mRS score > 2. RESULTS: From June 2014 to May 2021, 1010 patients were recruited in TOBAS. Embolization was chosen as the primary curative treatment for 116 patients and pre-embolization prior to surgery or SRS for 92 patients. Clinical and angiographic outcomes were available in 106 (91%) of 116 and 77 (84%) of 92 patients, respectively. In the curative embolization registry, 70% of AVMs were ruptured, and 62% were low-grade AVMs (Spetzler-Martin grade I or II), while the pre-embolization registry had 70% ruptured AVMs and 58% low-grade AVMs. The primary outcome of death or disability (mRS score > 2) occurred in 15 (14%, 95% CI 8%-22%) of the 106 patients in the curative embolization registry (4 [12%, 95% CI 5%-28%] of 32 unruptured AVMs and 11 [15%, 95% CI 8%-25%] of 74 ruptured AVMs) and 9 (12%, 95% CI 6%-21%) of the 77 patients in the pre-embolization registry (4 [17%, 95% CI 7%-37%] of 23 unruptured AVMs and 5 [9%, 95% CI 4%-20%] of 54 ruptured AVMs) at 2 years. Embolization alone was confirmed to occlude the AVM in 32 (30%, 95% CI 21%-40%) of the 106 curative attempts and in 9 (12%, 95% CI 6%-21%) of 77 patients in the pre-embolization registry. SAEs occurred in 28 of the 106 attempted curative patients (26%, 95% CI 18%-35%, including 21 new symptomatic hemorrhages [20%, 95% CI 13%-29%]). Five of the new hemorrhages were in previously unruptured AVMs (n = 32; 16%, 95% CI 5%-33%). Of the 77 pre-embolization patients, 18 had SAEs (23%, 95% CI 15%-34%), including 12 new symptomatic hemorrhages [16%, 95% CI 9%-26%]). Three of the hemorrhages were in previously unruptured AVMs (3/23; 13%, 95% CI 3%-34%). CONCLUSIONS: Embolization as a curative treatment for brain AVMs was often incomplete. Hemorrhagic complications were frequent, even when the specified intent was pre-embolization before surgery or SRS. Because the role of endovascular treatment remains uncertain, it should preferably, when possible, be offered in the context of a randomized trial.
引用
- Raymond J, Gentric JC, Magro E, et al. Endovascular treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial. J Neurosurg. 2022. PMID: 37132535. doi:10.3171/2022.9.JNS22987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。